Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)
CONCLUSIONS: Dabrafenib + trametinib was well tolerated and demonstrated a high rate of durable responses in patients with heavily pretreated recurrent/refractory BRAF V600E-mutated HCL.DisclosuresKreitman: NIH: Patents & Royalties: Co-inventor on the NIH patent for Moxetumomab Pasudotox. Moreau: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Blay: Roche: Honoraria, Other: Non-financial support, Research Funding; Novartis: Honoraria, Other: Non-financial support, Research Funding. Wainberg: Merck: Consultancy; EMD Serono: Consultancy; Lilly: Consultancy; Five Prime: Consultancy; Novartis: Consultancy. Stein: Novartis: Other: Patient documentation fees; GSK: Other: Patient documentation fees. Willenbacher: Merck: Honoraria; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; BMS: Honoraria; Novartis: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Amgen: Honoraria, Other: Steering board, Research Funding. Ravandi: Macrogenix: Honoraria, Research Funding; Abbvie: Research Funding; Xencor: Research Funding; Aste...
Source: Blood - Category: Hematology Authors: Kreitman, R. J., Moreau, P., Hutchings, M., Gazzah, A., Blay, J.-Y., Wainberg, Z. A., Stein, A., Dietrich, S., de Jonge, M. J. A., Willenbacher, W., De Greve, J., Arons, E., Ravandi, F., Rangwala, F., Burgess, P., Mookerjee, B., Subbiah, V. Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma Source Type: research
More News: Adenocarcinoma | Anemia | Cancer | Cancer & Oncology | Cough | Employment | Genetics | Hairy Cell Leukemia | Headache | Hodgkin's Disease | Laboratory Medicine | Leukemia | Lung Cancer | Lymphoma | Melanoma | Merck | Migraine | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Nutrition | Pancreas | Pancreatic Cancer | Rituxan | Skin Cancer | Study | Thyroid | Thyroid Cancer | Toxicology